Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Early Phase 1
2(100.0%)
2Total
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02927158Recruiting

Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community

Role: collaborator

NCT04628338Early Phase 1Completed

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT01957709Early Phase 1Terminated

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

Role: collaborator

All 3 trials loaded